Inactive Instrument
Cerevel Therapeutics Holdings, Inc. Stock
Stocks
CERE
US15678U1280
Biotechnology & Medical Research
| 1 day | +0.74% |
| 3 years | 21.86 |  | 44.99 |
| 5 years | 19.59 | | 46.16 |
| 10 years | 9 | | 46.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
John Renger
CTO | Chief Tech/Sci/R&D Officer | 57 | 01/05/2019 |
Matthew Calistri
IRC | Investor Relations Contact | - | - |
Paul Burgess
PRN | Corporate Officer/Principal | 53 | 20/06/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Deborah Baron
BRD | Director/Board Member | 57 | 20/01/2021 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 01/08/24 | Issuer sale | Chief Medical Officer | 1,495,399 | 0.8208% | ||
| 01/08/24 | Issuer sale | Director | 108,985 | 0.0598% | ||
| 01/08/24 | Issuer sale | Director | 137,525 | 0.0755% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.74% | -.--% | - | - | 8.19B | |
| -2.37% | -5.03% | +39.49% | +62.39% | 62.23B | |
| +1.43% | +1.71% | +12.17% | +71.01% | 54.92B | |
| +0.59% | +2.08% | +20.36% | +97.20% | 55.26B | |
| -0.07% | -5.49% | +20.00% | +30.15% | 42.59B | |
| -1.99% | -3.76% | +12.96% | +91.69% | 41.08B | |
| +3.11% | +5.31% | +230.54% | +784.97% | 40.33B | |
| +1.28% | +25.46% | +101.66% | +86.14% | 33.12B | |
| +0.21% | +1.05% | +14.81% | +46.96% | 32.61B | |
| -1.17% | +15.94% | -40.88% | +343.04% | 23.98B | |
| Average | +0.23% | +4.27% | +45.68% | +179.28% | 42.9B | |
| Weighted average by Cap. | +0.13% | +2.74% | +46.11% | +161.80% |
Employees
355
